18 reports

AS A RESULT, PHYSICIANS MAY EXPECT POSITIVE CV OUTCOMES DATA BEFORE PRESCRIBING NEW LIPID-MODIFYING DRUG THERAPIES TO THE WIDER DYSLIPIDEMIA POPULATION.

  • Lipid Modifying Drug
  • AstraZeneca PLC
  • Cerenis
  • Merck & Co., Inc.
  • The Medicines Company
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • World
  • Product Initiative
  • EVOLOCUMAB - DRUG PROFILE

The trials will evaluate alirocumab in combination with other lipid-lowering agents or as monotherapy across a broad patient population, including high cardiovascular risk patients with primary hypercholesterolemia, patients with primary hypercholesterolemia unable to tolerate stat

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • United States
  • Company
  • Product Initiative
  • 5. All the trials included are unique trials.

CLINICAL TRIALS BY PHASE IN E## COUNTRIES LIPID DISORDERS THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* LIPID DISORDERS THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* LIPID DISORDERS THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* Coun

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • World
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • World
  • Product Initiative
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Fruits on Lipid Profile in Dyslipidemia Patients Effects of Rhus Coriaria L.

  • Cardiovascular Disease
  • Cholesterol
  • Clinical Trial
  • Lipid Modifying Drug
  • World

The overall global pivotal Phase ## program is expected to enroll approximately ##, ## patients at high CVD risk with hypercholesterolemia on optimized background lipid-modifying therapy.

  • Cardiovascular Disease
  • Clinical Trial
  • Hospital
  • Lipid Modifying Drug
  • World

Department of Veterans Affairs Joslin Diabetes Center ## Jan 2007 ## Aug 2010 ## ## ## ## A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-##) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Ves

  • Cardiovascular Disease
  • Clinical Trial
  • Hospital
  • Lipid Modifying Drug
  • World
  • EVOLOCUMAB - DRUG PROFILE

Phase III - Trial Details EVOLOCUMAB - DRUG PROFILE Product Description Evolocumab (AMG-##, Repatha) is a monoclonal antibody acts as lipid modifying agent.

  • Cholesterol
  • Lipid Modifying Drug
  • United States
  • Product Initiative
  • Amgen Inc.

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Inhibitor Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Phase I Clinical Trial of PF-## Phase I Clinical Trial of PF-## GDCT## GDC##, Cardiovascular Atherosclerosis, R

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • World
  • EVOLOCUMAB - DRUG PROFILE

Other Developmental Activities Product Description EVOLOCUMAB - DRUG PROFILE Evolocumab (AMG-##, Repatha) is a monoclonal antibody acts as lipid modifying agent.

  • Endocrine Disease
  • Lipid Modifying Drug
  • United States
  • Company
  • Product Initiative

EFFECTIVENESS OF COMBINATION THERAPY WITH STATIN AND ANOTHER LIPID- MODIFYING AGENT COMPARED WITH INTENSIFIED STATIN MONOTHERAPY: A SYSTEMATIC REVIEW.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

R& D Progress Research and Development Brief In 2011, MLT in licensed the lipid-altering agent Gemcabene (also known as CI-## and PD ##) from Pfizer.

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • United States
  • Company Operations
  • Product Initiative

AS A RESULT, PHYSICIANS MAY EXPECT SIMILARLY STRINGENT STUDIES FOR NEW LIPID-MODIFYING DRUG THERAPIES.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

RECENT CLINICAL STUDIES OF THE EFFECTS OF LIPID-MODIFYING THERAPIES.

  • Lipid Modifying Drug
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.

EFFECTIVENESS OF COMBINATION THERAPY WITH STATIN AND ANOTHER LIPID- MODIFYING AGENT COMPARED WITH INTENSIFIED STATIN MONOTHERAPY: A SYSTEMATIC REVIEW.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

EFFECTIVENESS OF COMBINATION THERAPY WITH STATIN AND ANOTHER LIPID- MODIFYING AGENT COMPARED WITH INTENSIFIED STATIN MONOTHERAPY: A SYSTEMATIC REVIEW.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • AND APO B GENE SILENCERS

The trial recruited ##, ## patients from ## countries and investigated the lipid-modifying capacity of the drug in combination with statins with or without other lipid-modifying agents.

  • Lipid Modifying Drug
  • United States
  • Demand
  • Pfizer Inc.
  • Sanofi S.A.